GWM
CTKB icon

Gilpin Wealth Management’s Cytek Biosciences CTKB Stock Holding History

Gilpin Wealth Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$36 Sell
6
-3
-33% -$14 ﹤0.01% 1409
2026
Q2 		$40 Sell
9
-4
-31% -$17 ﹤0.01% 1054
2026
Q1 		$57 Buy
13
+4
+44% +$19 ﹤0.01% 981
2025
Q4 		$46 Buy
+9
New +$42 ﹤0.01% 956

Other funds holding CTKB

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
DCM
Davis Capital Management Jacksonville, Florida $167M AUM 17.17% 1-Year Est. Return

Gilpin Wealth Management's CTKB Position: Q3 2026 in Review

Gilpin Wealth Management reduced its Cytek Biosciences (CTKB) stake by 33% in Q3 2026, selling an estimated $14 and leaving 6 shares worth $36. The position accounts for ﹤0.01% of the portfolio, ranked #1409.

Gilpin Wealth Management first reported a position in CTKB in Q4 2025 and has held it in 4 quarters since. The position peaked at $57 in Q1 2026. 9 funds tracked by Wall St. Rank hold CTKB as of Q3 2026.

  • Gilpin Wealth Management held 6 shares of Cytek Biosciences worth $36 as of Q3 2026.
  • Gilpin Wealth Management sold 3 Cytek Biosciences shares in Q3 2026, an estimated $14.
  • Cytek Biosciences made up ﹤0.01% of Gilpin Wealth Management's portfolio in Q3 2026, its #1409 holding.
  • Gilpin Wealth Management first reported a position in Cytek Biosciences in Q4 2025 and has held it in 4 quarters since.
  • Gilpin Wealth Management's Cytek Biosciences position peaked at $57 in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2026.

Based on Gilpin Wealth Management's 13F filing for Q3 2026, filed 9 Oct 2026.